Skip to content

Released Nov 6, 2018, after the close

10-Q filed Nov 6, 2018, 37 days after period end · 0001232524-18-000192

Q3 2018 · 10-Q
Revenue$469.37M+14.0% vs Q3 2017−6.2% vs Q2 2018
Net Income$149.32M+135.0% vs Q3 2017+61.7% vs Q2 2018
EPS Diluted$2.41+134.0% vs Q3 2017+60.7% vs Q2 2018
Gross Profit$438,623,000+16.4%
Operating Income$188,777,000+118.4%
Operating Cash Flowderived$221,475,000+17.2%
Free Cash Flowderived$217,535,000+20.5%
Margins · derived
Gross margin93.4%+2.0 pt vs Q3 2017
Operating margin40.2%+19.2 pt vs Q3 2017
Net margin31.8%+16.4 pt vs Q3 2017

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2018Q3 2017Q3 2016Q3 2015
Revenue$469.37M$411.86M$374.18M$340.87M
Net Income$149.32M$63.53M$89.83M$87.96M
EPS Diluted$2.41$1.03$1.45$1.39

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR